, Volume 63, Issue 4, pp 319–323 | Cite as

Nanomaterials in controlled drug release

  • Xin-Jun Cai
  • Ying-Ying XuEmail author


In past years with the advances of chemistry and material sciences, the development of nanotechnology brought generations of nanomaterials with specific biomedical properties. These include the nanoparticle-based drug delivery, nanosized drugs, and nanomaterials for tissue engineering. The present article focuses on the use of nanomaterials in controlled drug release. The applications of nanomaterials with nano-enabled drug release characteristics brought many benefits when compared to the traditional (bulk) materials. We discuss the current advances and propose some future directions for the technology development.


Drug release Nanomaterial Nanoparticle Gel Colloid Drug delivery Self-assembly 


  1. Alexander JJ, Hauswirth WW (2008) Adeno-associated viral vectors and the retina. Adv Exp Med Biol 613:121–128CrossRefGoogle Scholar
  2. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH (2010) Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J Drug Target 18:381–388CrossRefGoogle Scholar
  3. Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, Bhavna (2010) Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 16(14):1644–1653CrossRefGoogle Scholar
  4. Betbeder D, Spérandio S, Latapie JP, de Nadai J, Etienne A, Zajac JM, Francés B (2000) Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 17:743–748CrossRefGoogle Scholar
  5. Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M (2009) Lipid nanoparticles for drug delivery to the brain: in vivo veritas. J Biomed Nanotechnol 5:344–350CrossRefGoogle Scholar
  6. Bok D (2004) Gene therapy of retinal dystrophies: achievements, challenges and prospects. Novartis Found Symp 255:4–12 discussion -6, 177–178CrossRefGoogle Scholar
  7. Buch PK, Bainbridge JW, Ali RR (2008) AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 15:849–857CrossRefGoogle Scholar
  8. Caruso G, Raudino G, Caffo M, Alafaci C, Granata F, Lucerna S, Salpietro FM, Tomasello F (2010) Nanotechnology platforms in diagnosis and treatment of primary brain tumors. Recent Pat Nanotechnol 4(2):119–124Google Scholar
  9. Charlton S, Jones NS, Davis SS, Illum L (2007) Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci 30:295–302CrossRefGoogle Scholar
  10. Chekhonin VP, Baklaushev VP, Iusubalieva GM (2009) Prospects for targeted therapy for gliomas. Vestn Ross Akad Med Nauk (4):30–42Google Scholar
  11. Collier JH, Rudra JS, Gasiorowski JZ, Jung JP (2010) Multi-component extracellular matrices based on peptide self-assembly. Chem Soc Rev 39:3413–3424CrossRefGoogle Scholar
  12. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G (2009) Recent advances in medicinal chemistry and pharmaceutical technology–strategies for drug delivery to the brain. Curr Top Med Chem 9:182–196CrossRefGoogle Scholar
  13. Ellis-Behnke RG, Liang YX, Tay DK, Kau PW, Schneider GE, Zhang S, Wu W, So KF (2006a) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2:207–215Google Scholar
  14. Ellis-Behnke RG, Liang YX, You SW, Tay DK, Zhang S, So KF, Schneider GE (2006b) Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 103:5054–5059CrossRefGoogle Scholar
  15. Fisher RS, Ho J (2002) Potential new methods for antiepileptic drug delivery. CNS Drugs 16:579–593CrossRefGoogle Scholar
  16. Fonseca SB, Pereira MP, Kelley SO (2009) Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61:953–964CrossRefGoogle Scholar
  17. Gilmore JL, Yi X, Quan L, Kabanov AV (2008) Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol 3:83–94CrossRefGoogle Scholar
  18. Graf A, McDowell A, Rades T (2009) Poly(alkylcyanoacrylate) nanoparticles for enhanced delivery of therapeutics—is there real potential? Expert Opin Drug Deliv 6:371–387CrossRefGoogle Scholar
  19. Grieger JC, Samulski RJ (2005) Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 99:119–145Google Scholar
  20. Guo J, Su H, Zeng Y, Liang YX, Wong WM, Ellis-Behnke RG, So KF, Wu W (2007) Reknitting the injured spinal cord by self-assembling peptide nanofiber scaffold. Nanomedicine 3:311–321Google Scholar
  21. Heilbronn R, Weger S (2010) Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol (197):143–170Google Scholar
  22. Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379:201–209CrossRefGoogle Scholar
  23. Jatariu A, Peptu C, Popa M, Indrei A (2009) Micro- and nanoparticles—medical applications. Rev Med Chir Soc Med Nat Iasi 113:1160–1169Google Scholar
  24. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR (2008) Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 22:116–124CrossRefGoogle Scholar
  25. Kateb B, Chiu K, Black KL, Yamamoto V, Khalsa B, Ljubimova JY, Ding H, Patil R, Portilla-Arias JA, Modo M, Moore DF, Farahani K, Okun MS, Prakash N, Neman J, Ahdoot D, Grundfest W, Nikzad S, Heiss JD (2010) Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage 54(Suppl 1):S106–S124Google Scholar
  26. Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109CrossRefGoogle Scholar
  27. Khalil NM, Mainardes RM (2009) Colloidal polymeric nanoparticles and brain drug delivery. Curr Drug Deliv 6:261–273Google Scholar
  28. Kopecek J, Yang J (2009) Peptide-directed self-assembly of hydrogels. Acta Biomater 5:805–816CrossRefGoogle Scholar
  29. Kumar M, Misra A, Pathak K (2009) Formulation and characterization of nanoemulsion of olanzapine for intranasal delivery. PDA J Pharm Sci Technol 63:501–511Google Scholar
  30. Ling PM, Cheung SW, Tay DK, Ellis-Behnke RG (2011) Using self-assembled nanomaterials to inhibit the formation of metastatic cancer stem cell colonies in vitro. Cell Transplant 20:127–131CrossRefGoogle Scholar
  31. Ljubimova JY, Fujita M, Ljubimov AV, Torchilin VP, Black KL, Holler E (2008) Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) 3:247–265CrossRefGoogle Scholar
  32. Martin KR, Klein RL, Quigley HA (2002) Gene delivery to the eye using adeno-associated viral vectors. Methods 28:267–275CrossRefGoogle Scholar
  33. Mistry A, Glud SZ, Kjems J, Randel J, Howard KA, Stolnik S, Illum L (2009a) Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J Drug Target 17:543–552CrossRefGoogle Scholar
  34. Mistry A, Stolnik S, Illum L (2009b) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–157CrossRefGoogle Scholar
  35. Modi G, Pillay V, Choonara YE (2010) Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci 1184:154–172CrossRefGoogle Scholar
  36. Namdeo M, Saxena S, Tankhiwale R, Bajpai M, Mohan YM, Bajpai SK (2008) Magnetic nanoparticles for drug delivery applications. J Nanosci Nanotechnol 8:3247–3271CrossRefGoogle Scholar
  37. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, Tokuhara D, Kurokawa S, Takahashi Y, Tsukada H, Kozaki S, Akiyoshi K, Kiyono H (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9:572–578Google Scholar
  38. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C (2004) Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437–445Google Scholar
  39. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF (2009) Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23:35–58CrossRefGoogle Scholar
  40. Poeschla EM (2003) Non-primate lentiviral vectors. Curr Opin Mol Ther 5:529–540Google Scholar
  41. Provenzale JM, Silva GA (2009) Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am J Neuroradiol 30:1293–1301CrossRefGoogle Scholar
  42. Shilpi S, Jain A, Gupta Y, Jain SK (2007) Colloidosomes: an emerging vesicular system in drug delivery. Crit Rev Ther Drug Carrier Syst 24:361–391Google Scholar
  43. Sleeper MM, Bish LT, Sweeney HL (2009) Gene therapy in large animal models of human cardiovascular genetic disease. ILAR J 50:199–205Google Scholar
  44. Surace EM, Auricchio A (2003) Adeno-associated viral vectors for retinal gene transfer. Prog Retin Eye Res 22:705–719CrossRefGoogle Scholar
  45. Surace EM, Auricchio A (2008) Versatility of AAV vectors for retinal gene transfer. Vision Res 48:353–359CrossRefGoogle Scholar
  46. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:16CrossRefGoogle Scholar
  47. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5:155–174CrossRefGoogle Scholar
  48. Wong HL, Chattopadhyay N, Wu XY, Bendayan R (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 62:503–517CrossRefGoogle Scholar
  49. Zhao X, Pan F, Xu H, Yaseen M, Shan H, Hauser CA, Zhang S, Lu JR (2010) Molecular self-assembly and applications of designer peptide amphiphiles. Chem Soc Rev 39:3480–3498CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of pharmacyIntegrated Chinese and Western Medicine Hospital of Zhejiang ProvinceHangzhouChina

Personalised recommendations